MLchartDataset catalogue

anti-GARP monoclonal antibody JYB 1907

Term · Oncology and biomedicine · MLC-T-ONC-010681

A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody JYB1907 selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine transforming growth factor-beta 1 (TGF-b1), thereby relieving the immunosuppression caused by TGF-b1 and reversing the immunosuppressive nature in the tumor microenvironment (TME). This improves anti-tumor immune responses GARP, a transmembrane protein highly expressed on activated, immunosuppressive regulatory T cells (Tregs) in the TME, is essential for the expression of TGF-b1 on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs. TGF-b1 stimulates stromal cell proliferation, neovascularization, cancer cell metastasis, and inhibits immune cell infiltration.

Table 1. Record
IdentifierMLC-T-ONC-010681
FieldOncology and biomedicine
Synonymsanti-glycoprotein A repetitions predominant monoclonal antibody JYB1907
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-010681",
  "term": "anti-GARP monoclonal antibody JYB 1907",
  "field": "Oncology and biomedicine",
  "definition": "A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody JYB1907 selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine transforming growth factor-beta 1 (TGF-b1), thereby relieving the immunosuppression caused by TGF-b1 and reversing the immunosuppressive nature in the tumor microenvironment (TME). This improves anti-tumor immune responses GARP, a transmembrane protein highly expressed on activated, immunosuppressive regulatory T cells (Tregs) in the TME, is essential for the expression of TGF-b1 on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs. TGF-b1 stimulates stromal cell proliferation, neovascularization, cancer cell metastasis, and inhibits immune cell infiltration.",
  "synonyms": [
    "anti-glycoprotein A repetitions predominant monoclonal antibody JYB1907"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-garp-monoclonal-antibody-jyb-1907/"
}

Record 1,784 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.